Home > Newsletters > FDAnews Drug Daily Bulletin > Bapineuzumab Failure Could Mean Bleak Outlook for Alzheimer’s Drugs
FDAnews Drug Daily Bulletin
Aug. 14, 2012 | Vol. 9 No. 159
Bapineuzumab Failure Could Mean Bleak Outlook for Alzheimer’s Drugs
Pfizer, Johnson & Johnson (J&J) and Elan’s termination of their late-stage program for investigational Alzheimer’s drug bapineuzumab following the second failed study may not negatively impact the companies but could foreshadow a bleak outlook for the future of Alzheimer’s drug development, analysts say. Bapineuzumab missed its co-primary endpoints, failing to improve cognitive and functional performance compared with placebo in Study 302, its second of four Phase III studies to report data, the companies said.
Washington Drug Letter
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.